US provider, clinical trial, claims and drug pricing data
3.9(2)4 published listings.
540,000 interventional and observational trials harmonised from public registries worldwide, with phases, conditions, sponsors, site locations, enrolment and status history.
WAC list price changes, NADAC acquisition costs and FDA approval events for 24,000 US drug products and 110,000 NDC package codes, linked by ingredient and manufacturer.
2.6 million US physicians, nurse practitioners and healthcare organisations keyed by NPI, with specialties, practice locations, hospital affiliations and licence status.
Quarterly counts and allowed costs by procedure, diagnosis group, drug and 3-digit ZIP region from de-identified US claims, certified by expert determination with small cells suppressed.
Willowbrook Health Data turns public healthcare registries and de-identified claims into analysis-ready datasets for pharma, payers and health-tech companies. It works only with professional, trial, product and aggregated data, and never sells patient-level records.
What the provider licenses its data for, and what it does not allow.
Healthcare professional targeting, trial site selection, market access, pricing analysis and health economics research.
Re-identifying patients, marketing to individual patients or consumers, and insurance or employment decisions about individuals.
DataStoa's acceptable use policy applies on top: no re-identification, discrimination, surveillance or sanctioned uses.
Provider-reported. Ask for certificates or a data processing agreement before you sign.
Other places you can receive this provider's data, useful if your team already buys through a cloud marketplace.
Buyers rate four things: data quality, volume and coverage, value for money and service.
from 2 reviews
Procedure volumes by region gave us a defensible market size for a new device. Small cells are suppressed, so rare procedures in small regions come back empty, which is the correct trade-off for de-identified data.
Carlos E., Market access analyst, Medical device maker
Provider-to-hospital and group-practice affiliations were more current than our previous source, which improved territory alignment. Price is at the high end, so we licensed the national file without the API.
Beth A., Commercial analytics director, Specialty pharma company